# AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both

Study · id `cardio:ct-nct07931573` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07931573](<https://clinicaltrials.gov/study/NCT07931573>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07931573

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 1200 participants.

## Technical summary

Registry record NCT07931573. Randomized; quadruple masking; primary purpose treatment. Start 2026-11-10 (anticipated); primary completion 2028-07-04 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 1200 participants (planned count; ClinicalTrials.gov record NCT07931573, source copy `cardio:ctgov-nct07931573-2026-11-12`, retrieved 2026-11-18)
- Planned start: 2026-11-10 (anticipated) (ClinicalTrials.gov record NCT07931573, source copy `cardio:ctgov-nct07931573-2026-11-12`, retrieved 2026-11-18)
- Primary completion: 2028-07-04 (anticipated) (ClinicalTrials.gov record NCT07931573, source copy `cardio:ctgov-nct07931573-2026-11-12`, retrieved 2026-11-18)
- Completion: 2028-08-08 (anticipated) (ClinicalTrials.gov record NCT07931573, source copy `cardio:ctgov-nct07931573-2026-11-12`, retrieved 2026-11-18)
- Countries: United States; Argentina; Australia; Brazil; Bulgaria; Canada; Croatia; Czechia; Denmark; Germany; Greece; Hungary; Israel; Italy; Poland; Portugal; Puerto Rico; Romania; Saudi Arabia; Slovakia; Spain; United Kingdom (ClinicalTrials.gov record NCT07931573, source copy `cardio:ctgov-nct07931573-2026-11-12`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07931573-2026-11-12`, retrieved 2026-11-18)

## The registry's words

- Brief title: AMBITION 3: A Research Study Investigating How Well Zenagamtide at Higher Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide in People With Type 2 Diabetes Treated With Metformin, SGLT2i, or Both
- Acronym: AMBITION 3
- Condition: Type 2 Diabetes
- Intervention (Drug): Zenagamtide
- Intervention (Drug): Semaglutide
- Intervention (Drug): Placebo
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Semaglutide (`cardio:semaglutide`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: cd5558c97ad2ba7918c5b2d5155aa34aa92e544055839a9e18bca6f5b44b9c44
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
